We analyzed CheckMate 025(CM‐025) (phase 3 trial of anti‐PD‐1 in 180 advanced RCC)[26] and IMvigor210(IV‐210) (Phase 2 study investigating anti‐PD‐L1 in metastatic urothelial cancer, including 66 carcinoma of renal pelvis)[27] data to test whether HOOK1 enhanced anti‐tumor immunity. This evidence concerns the gene CD274 and renal cell carcinoma.